3/26
02:04 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) was upgraded by analysts at StockNews.com to a "sell" rating.
Neutral
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) was upgraded by analysts at StockNews.com to a "sell" rating.
3/25
09:21 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock.
3/24
02:53 pm
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/24
07:05 am
mbrx
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
Neutral
Report
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
3/19
08:05 am
mbrx
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
Low
Report
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
3/13
02:08 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/11
09:13 am
mbrx
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference [Yahoo! Finance]
Medium
Report
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference [Yahoo! Finance]
3/11
08:45 am
mbrx
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Medium
Report
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
3/10
08:56 am
mbrx
Moleculin to Present at the 37th Annual ROTH Conference [Yahoo! Finance]
Medium
Report
Moleculin to Present at the 37th Annual ROTH Conference [Yahoo! Finance]
3/10
08:45 am
mbrx
Moleculin to Present at the 37th Annual ROTH Conference
Medium
Report
Moleculin to Present at the 37th Annual ROTH Conference
3/6
08:30 am
mbrx
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
Medium
Report
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
3/5
02:04 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/3
08:49 am
mbrx
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium [Yahoo! Finance]
Medium
Report
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium [Yahoo! Finance]
3/3
08:31 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/3
08:30 am
mbrx
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Medium
Report
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
2/25
01:17 pm
mbrx
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules [Yahoo! Finance]
Medium
Report
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules [Yahoo! Finance]
2/25
12:35 pm
mbrx
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
High
Report
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
2/25
02:07 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/17
01:31 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/13
01:49 pm
mbrx
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds [Yahoo! Finance]
High
Report
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds [Yahoo! Finance]
2/13
01:05 pm
mbrx
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
High
Report
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
2/13
09:25 am
mbrx
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
High
Report
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
2/12
08:45 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
High
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
2/11
08:57 am
mbrx
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial [Yahoo! Finance]
High
Report
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial [Yahoo! Finance]
2/11
08:40 am
mbrx
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
High
Report
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial